All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Jules Lin, MD
Disclosure(s): Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Intuitive Surgical: Robotic proctor (Ongoing); Lung Bioengineering: Advisory Board (Terminated, October 28, 2023); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, April 12, 2023)

Sanghoon Jheon, MD, PhD

Presentations

1. Current Evidence for Sublobar Resection for Lung Cancer: What Is and Is Not Known
   Masahiro Tsuboi, MD, Ph.D
   Disclosure(s): Astra Zeneca global: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca KK: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chugai Pharmaceutical CO.,LTD: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Advisory Board (Ongoing); Eli Lilly Japan: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson Japan: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic Japan: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MiRXES: Advisory Board (Ongoing); MSD KK: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ono Pharmaceutical CO.,LTD: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); stol-Myers Squibb KK: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Taiho Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Teijin Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 31, 2022)
    
2. The impact of margin distance on locoregional recurrence and survival after thoracoscopic segmentectomy
   Lin Huang, MD, PhD
    
3. Wedge Resection Results in Lower Perioperative Morbidity and Similar Long-term Survival Compared to Segmentectomy for Clinical Stage IA Lung Cancer Patients
   Christopher Towe, MD
   Disclosure(s): Astra Zeneca: Consultant (Terminated, October 1, 2023); AtriCure: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Terminated, October 1, 2023); Intutive Surigcal: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Zimmer Biomet: Consultant (Ongoing)
    
4. State-of-the-Art Techniques for Sublobar Resection
   Jules Lin, MD
   Disclosure(s): Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Intuitive Surgical: Robotic proctor (Ongoing); Lung Bioengineering: Advisory Board (Terminated, October 28, 2023); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, April 12, 2023)
    
5. What is an adequate parenchymal margin during sublobar resection of subsolid adenocarcinomas?
   Devanish Narasimhasanth Kamtam, MBBS, MS
    
6. Available (or Emerging) Tools for Pre-operative Planning in Sublobar Resection
   Samuel Kim, MD
    
7. Where Does Sublobar Resection Fit in the Evolving World of Lung Cancer Therapies?
   Alan D. Sihoe, MBBChir, MA, FRCSEd(CTh), FCCP, FACS
   Disclosure(s): , Medtronic: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Astra Zeneca: Consultant (Terminated); Medela: Advisory Board (Ongoing); Roche: Consultant (Ongoing)